Stocktoria
CRYO CELL INTERNATIONAL INC CCEL
CRYO CELL INTERNATIONAL INC (CCEL) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the distress zone. It pays a dividend yielding 12.08% (safety: safe). FY2025 revenue was $31.6M at a -7.7% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -3.21 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | -0.13 |
| Retained earnings / assets | -0.623 |
| EBIT / assets | 0.008 |
| Equity / liabilities | -0.232 |
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| CCEL | CRYO CELL INTERNATIONAL INC | 5/9 | -3.07 | — | -1.3% |
| NIVF | NewGenIvf Group Ltd | 3/9 | 3.84 | 0.6 | — |
| MGRX | MANGOCEUTICALS, INC. | 2/9 | 2.42 | — | — |
| BRTX | BioRestorative Therapies, Inc. | 3/9 | — | — | — |
| VMD | VIEMED HEALTHCARE, INC. | 5/9 | 5.41 | 26.5 | +20.5% |
| SHC | Sotera Health Co | 6/9 | — | 63.6 | +5.7% |
| PGNY | Progyny, Inc. | 5/9 | 7.14 | 38.2 | +10.4% |
About CRYO CELL INTERNATIONAL INC
Cryo-Cell International, Inc. engages in cord blood and cord tissue cryopreservation services in the United States. The company offers cellular processing and cryogenic storage for family use, primarily for collection and preservation of umbilical cord blood, and tissue stem cells; and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. It is also involved in the manufacturing of PrepaCyte CB processing system units for processing umbilical cord blood stem cells. In addition, the company provides cold storage services to third-party pharmaceutical companies and medical institutions. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. The company was incorporated in 1989 and is headquartered in Oldsmar, Florida.
FAQ
Is CCEL financially healthy?
CRYO CELL INTERNATIONAL INC's Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does CCEL pay a dividend, and is it safe?
Yes. CRYO CELL INTERNATIONAL INC pays a dividend yielding about 12.08% with a -133.0% payout ratio, rated “safe” for safety.
How profitable is CCEL?
In FY2025, CRYO CELL INTERNATIONAL INC had a net margin of -7.7%.
Is CCEL overvalued or undervalued?
CRYO CELL INTERNATIONAL INC trades at about 77.6× trailing earnings — above its 10-year norm (10-year range 3.9×–148.2×, median 32.2×). Stocktoria reports the data, not buy/sell advice.
Is CCEL a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on CRYO CELL INTERNATIONAL INC: a Piotroski F-score of 5/9, an Altman Z″ in the distress zone, a dividend yield of 12.08%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-11-30. Facts plus Stocktoria's own computed scores — not investment advice.